Default company panoramic image
E9fdb633 2b09 478b 8ea8 c82f796a46e7

ImmunoProp Pharma, Inc.

ImmunoProp has four marketed products focused on chronic fatigue. Ours is the most effective therapy for this large and underserved market.

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location New York City, NY, USA
  • Currency USD
  • Website immunoprop.com

Company Summary

ImmunoProp Pharma, Inc. manufactures, markets and distributes four over-the-counter products for the treatment of chronic fatigue syndrome and fibromyalgia. The Company markets the products mainly through Dr. Derek Enlander's medical practice and its website (www.immunoprop.com). ImmunoProp is profitable. The Company is raising $2 million to expand distribution and fund a commercial-scale launch.

Team

  • Default avatar
    David Goggin
    Chief Operating Officer

    David Goggin has primary responsibility for the Company’s finances and operations. Before joining ImmunoProp, David served as CFO of Entelos, a computational biology company. His background includes nine years in investment banking with Deutsche Bank and CIBC World Markets (now Oppenheimer), where he advised specialty pharmaceutical, biotechnology and medical technology companies. David is a CPA and holds an MBA from Columbia University.

  • Default avatar
    Derek Enlander
    Founder and Director

    Dr. Enlander is an internal medicine physician based in New York City. He is considered one of the world’s leading authorities in chronic fatigue syndrome and fibromyalgia.

    He serves on the faculty of Mount Sinai Medical School and is President of the Israel Medical Research Foundation.

    Dr. Enlander holds an M.D. degree from Stanford University. He is the editor of an international peer reviewed medical journal, The Fatigue Journal.

  • Default avatar
    Barry Cohen
    Director

    Barry Cohen is a retired pharmaceutical executive. Mr. Cohen was a Senior Vice President of Merck and President of Merck Sharp & Dohme, with responsibilities for the sale of Merck’s prescription drugs in Europe, Japan and the Middle East.

    Since 1994, Mr. Cohen has served as Chairman of the Board of Vasomedical. He has also served as a director of Akzo Nobel, Chugai Pharmaceutical, Neurobiological Technologies, and Teva Pharmaceutical.

Previous Investors

  • Default avatar
    Derek Enlander
    Unconfirmed
    Default avatar
    Barry Cohen
    Unconfirmed